Citi analyst Peter Verdult upgraded UCB to Buy from Neutral with a price target of EUR 108, up from EUR 84. The firm says its benchmarking analysis demonstrates the Bimzelx psoriasis launch is exceeding expectations, despite a highly competitive U.S. landscape.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on UCBJF: